Drug Search Results

Perifosine

Alternative Names: perifosine
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Akt Inhibitor,PI3K Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AEterna Zentaris
Company Location: MONTREAL A8 H3B 3V2
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Perifosine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Multiple Myeloma|Colorectal Cancer

Phase 2: Leukemia|Prostate Cancer|Waldenstrom Macroglobulinemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Colorectal Cancer|Renal Cell Carcinoma|Lymphoma|Lymphoma, B-Cell|Oligodendroglioma|Endometrial Cancer|Multiple Myeloma|Glioblastoma|Melanoma|Non-Small-Cell Lung Cancer|Sarcoma|Adenocarcinoma|Gliosarcoma|Head and Neck Cancer|Pancreatic Cancer|Brain Cancer|Glioma|Astrocytoma|Gastrointestinal Stromal Tumors|Cervical Cancer|Kidney Cancer|Alveolar Soft Part Sarcoma|Breast Cancer|Chondrosarcoma|Ovarian Cancer

Phase 1: Heart Failure, Acute|Angina, Stable|Heart Failure, Chronic|Hepatitis B, Chronic|Hepatitis C, Chronic|Hypokalemia|HIV Infections|Torsades de Pointes|Angina Pectoris|Hypertrophy, Left Ventricular|Angina, Unstable|Pregnancy Outcomes|Myocardial Infarction|Renal Cell Carcinoma|Multiple Myeloma|Surgical Wound Infection|Contraception|Liver Cancer|Oncology Solid Tumor Unspecified|Colorectal Cancer|Kidney Cancer|Neuromyelitis Optica|Myelodysplastic-Myeloproliferative Diseases|Lymphoma|Myelodysplastic Syndrome|Preleukemia|Myeloproliferative Disorders|Prostate Cancer|Diarrhea|Astrocytoma|Acute Lymphoid Leukemia|Oligodendroglioma|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia|Chronic Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Myeloid, Accelerated Leukemia|Acute Myelomonocytic Leukemia|Adult T-Cell Leukemia-Lymphoma|Glioblastoma|Neuroblastoma|Blast Crisis|Brain Cancer|Acute Promyelocytic Leukemia|Chronic Myelomonocytic Leukemia|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Erythroblastic Leukemia|Ovarian Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
NCT00590954	P2	Completed	Glioma\|Brain Cancer	2019-11-11
NCI-2011-01409	P2	Completed	Astrocytoma\|Oligodendroglioma\|Glioblastoma\|Gliosarcoma	2018-11-16
AAAM3801	P1	Completed	Astrocytoma\|Oligodendroglioma\|Brain Cancer\|Glioblastoma	2017-10-27
NCT00776867	P1	Completed	Oncology Solid Tumor Unspecified	2017-07-01

Recent News Events

Date	Type	Title
03/01/2024	PubMed	Neuroprotective effects of Rehmannia glutinosa polysaccharide on chronic constant light (CCL)-induced oxidative stress and autophagic cell death via the AKT/mTOR pathway in mouse hippocampus and HT-22 cells.
02/01/2024	PubMed	Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells.
01/15/2024	PubMed	ROS/mtROS promotes TNTs formation via the PI3K/AKT/mTOR pathway to protect against mitochondrial damages in glial cells induced by engineered nanomaterials.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.